Xenetic Biosciences (XBIO) Equity Ratio (2023 - 2025)
Xenetic Biosciences' Equity Ratio history spans 6 years, with the latest figure at 0.88 for Q4 2025.
- For Q4 2025, Equity Ratio rose 1.59% year-over-year to 0.88; the TTM value through Dec 2025 reached 0.88, up 1.59%, while the annual FY2025 figure was 0.88, 1.59% up from the prior year.
- Equity Ratio reached 0.88 in Q4 2025 per XBIO's latest filing, up from 0.78 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.94 in Q1 2023 to a low of 0.78 in Q3 2025.
- Average Equity Ratio over 3 years is 0.88, with a median of 0.88 recorded in 2025.
- Peak YoY movement for Equity Ratio: dropped 11.53% in 2024, then grew 1.59% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.92 in 2023, then dropped by 5.76% to 0.87 in 2024, then increased by 1.59% to 0.88 in 2025.
- Per Business Quant, the three most recent readings for XBIO's Equity Ratio are 0.88 (Q4 2025), 0.78 (Q3 2025), and 0.83 (Q2 2025).